<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632474</url>
  </required_header>
  <id_info>
    <org_study_id>FSCII-ART-1</org_study_id>
    <nct_id>NCT02632474</nct_id>
  </id_info>
  <brief_title>ART Drug Dosage Adjustment in HIV-infected Population</brief_title>
  <official_title>ART Drug Dosage Adjustment Using FSCII in Chinese HIV-infected Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of the combination of low dose of
      Tenofovir, Efavirenz and Lamivudine in treating HIV-infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The feedback system control (FSC) technique has been developed to rapidly identify optimal
      combinations for therapeutic purposes. Low dose of TDF+3TC+EFV combination has been test in
      vitro study by FSC which showed high efficacy and now the investigators apply it to human to
      further optimize the ART combination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV viral load</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 Count</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug Plasma Concentration</measure>
    <time_frame>Day 7,14,21,28</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Low-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)</intervention_name>
    <description>The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).</description>
    <arm_group_label>Low-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV antibody positive

          -  HIV RNA below 10*E5 copies/ml

          -  CD4 T cell count above 200 cells/ml

          -  Provision of written informed consent

        Exclusion Criteria:

          -  HIV genotyping resistant to investigating drug

          -  Pregnant, breastfeeding, or lactating

          -  Any serious or active medical or psychiatric illness which, in the opinion of the
             Investigator, would interfere with treatment, assessment, compliance with the
             protocol, or subject safety. This would include any active clinically significant
             renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease)
             illness, or malignancy

          -  Medical or psychiatric condition or occupational responsibilities that may preclude
             compliance with the protocol

          -  Laboratory blood values:

          -  Haemoglobin &lt;7.0 grams/decilitre (g/dL)

          -  Neutrophil count &lt;500/mm3

          -  Platelet count &lt;50,000/mm3

          -  Aspartate aminotransferase or Alanine transaminase &gt;5 times Upper Limit of Normal
             (ULN)

          -  Subjects with an estimated creatinine clearance of &lt;50 mL/minute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>HIV Infections</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Efavirenz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

